CA2960950C - Treatment of fibrodysplasia ossificans progressiva - Google Patents

Treatment of fibrodysplasia ossificans progressiva Download PDF

Info

Publication number
CA2960950C
CA2960950C CA2960950A CA2960950A CA2960950C CA 2960950 C CA2960950 C CA 2960950C CA 2960950 A CA2960950 A CA 2960950A CA 2960950 A CA2960950 A CA 2960950A CA 2960950 C CA2960950 C CA 2960950C
Authority
CA
Canada
Prior art keywords
antibody
acvr2a
acvr2b
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2960950A
Other languages
English (en)
French (fr)
Other versions
CA2960950A1 (en
Inventor
Sarah J. Hatsell
Aris N. Economides
Vincent J. Idone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA2960950A1 publication Critical patent/CA2960950A1/en
Application granted granted Critical
Publication of CA2960950C publication Critical patent/CA2960950C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2960950A 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva Active CA2960950C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462049869P 2014-09-12 2014-09-12
US62/049,869 2014-09-12
US201562141775P 2015-04-01 2015-04-01
US62/141,775 2015-04-01
PCT/US2015/000100 WO2016039796A2 (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Publications (2)

Publication Number Publication Date
CA2960950A1 CA2960950A1 (en) 2016-03-17
CA2960950C true CA2960950C (en) 2023-03-14

Family

ID=54207748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960950A Active CA2960950C (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Country Status (29)

Country Link
US (3) US20160075772A1 (enExample)
EP (2) EP3191512B1 (enExample)
JP (1) JP6560341B2 (enExample)
KR (1) KR102564079B1 (enExample)
CN (1) CN107106648B (enExample)
AU (1) AU2015315829B2 (enExample)
CA (1) CA2960950C (enExample)
CL (2) CL2017000603A1 (enExample)
CY (1) CY1122188T1 (enExample)
DK (1) DK3191512T3 (enExample)
ES (1) ES2739605T3 (enExample)
HR (1) HRP20191929T1 (enExample)
HU (1) HUE046558T2 (enExample)
IL (1) IL251063B (enExample)
LT (1) LT3191512T (enExample)
MA (1) MA40621B1 (enExample)
ME (1) ME03541B (enExample)
MX (1) MX382026B (enExample)
MY (1) MY179654A (enExample)
NZ (1) NZ730773A (enExample)
PL (1) PL3191512T3 (enExample)
PT (1) PT3191512T (enExample)
RS (1) RS59412B1 (enExample)
SG (2) SG10201902175RA (enExample)
SI (1) SI3191512T1 (enExample)
SM (1) SMT201900584T1 (enExample)
TW (1) TWI688402B (enExample)
WO (1) WO2016039796A2 (enExample)
ZA (1) ZA201702112B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
JP6877357B2 (ja) 2015-04-15 2021-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
DK3286206T3 (da) 2015-04-22 2021-05-03 Biogen Ma Inc Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP3415527B1 (de) 2017-06-14 2025-12-10 Kymab Ltd. Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen
US11248044B2 (en) 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
CN111836643A (zh) * 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
EP3806627A1 (en) 2018-06-13 2021-04-21 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
CN112236166A (zh) 2018-06-13 2021-01-15 科马布有限公司 用于治疗骨疾病的转铁蛋白受体-2的拮抗剂和激动剂
AU2019316103B2 (en) 2018-08-02 2026-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20210322563A1 (en) * 2018-08-02 2021-10-21 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
AU2019364415A1 (en) * 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
EP3898672A1 (en) * 2018-12-18 2021-10-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
BR112022013589A2 (pt) 2020-01-08 2022-09-13 Regeneron Pharma Tratamento da fibrodisplasia ossificante progressiva
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
WO2021222875A1 (en) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
BR112022025700A2 (pt) 2020-06-18 2023-02-28 Regeneron Pharma Formulações de anticorpo de activina a e métodos de uso das mesmas
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CA3197104A1 (en) * 2020-11-11 2022-05-19 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CN119529092A (zh) * 2021-09-03 2025-02-28 来凯医药科技(上海)有限公司 抗acvr2a抗体及其用途
EP4713372A1 (en) * 2023-05-15 2026-03-25 Immunecare Biopharmaceuticals (Shanghai) Co., Ltd Recombinant fusion protein for treatment of pulmonary hypertension

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
MXPA01007845A (es) 1999-02-05 2004-06-22 Samsung Electronics Co Ltd Metodo para la recuperacion de la textura de imagenes y aparato para el mismo.
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
CA2550551C (en) 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8859752B2 (en) * 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
EA200970250A1 (ru) * 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
JP5270913B2 (ja) 2007-12-26 2013-08-21 サンゴバン・ティーエム株式会社 高電気抵抗高ジルコニア鋳造耐火物
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
CN102946908B (zh) * 2010-06-18 2015-04-22 Lsip基金运营联合公司 显性等位基因表达抑制剂
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
RS56796B1 (sr) * 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
WO2014051109A1 (ja) 2012-09-28 2014-04-03 協和発酵キリン株式会社 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
CA2976446A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
AU2016255768B2 (en) 2015-04-29 2022-03-10 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva

Also Published As

Publication number Publication date
CL2017000603A1 (es) 2017-10-06
SI3191512T1 (sl) 2019-09-30
MA40621A (fr) 2017-07-19
US20200115440A1 (en) 2020-04-16
EP3191512B1 (en) 2019-07-24
HRP20191929T1 (hr) 2020-01-10
MA40621B1 (fr) 2019-11-29
CN107106648A (zh) 2017-08-29
CA2960950A1 (en) 2016-03-17
MX382026B (es) 2025-03-13
TWI688402B (zh) 2020-03-21
ZA201702112B (en) 2018-05-30
EP3191512A2 (en) 2017-07-19
CL2018002962A1 (es) 2018-12-28
JP6560341B2 (ja) 2019-08-14
SG10201902175RA (en) 2019-04-29
AU2015315829B2 (en) 2021-05-27
PT3191512T (pt) 2019-09-26
SMT201900584T1 (it) 2019-11-13
CY1122188T1 (el) 2020-11-25
US11407822B2 (en) 2022-08-09
KR20170052666A (ko) 2017-05-12
US20160075772A1 (en) 2016-03-17
LT3191512T (lt) 2019-09-10
KR102564079B1 (ko) 2023-08-08
BR112017004812A2 (pt) 2017-12-12
JP2017528476A (ja) 2017-09-28
EP3604335A1 (en) 2020-02-05
MX2017003175A (es) 2017-06-06
RS59412B1 (sr) 2019-11-29
IL251063B (en) 2022-08-01
NZ730773A (en) 2022-07-01
AU2015315829A1 (en) 2017-04-27
HUE046558T2 (hu) 2020-03-30
WO2016039796A2 (en) 2016-03-17
SG11201701913SA (en) 2017-04-27
ES2739605T3 (es) 2020-02-03
ME03541B (me) 2020-07-20
CN107106648B (zh) 2021-06-11
WO2016039796A3 (en) 2016-06-16
IL251063A0 (en) 2017-04-30
US20180111983A1 (en) 2018-04-26
TW201625302A (zh) 2016-07-16
MY179654A (en) 2020-11-11
DK3191512T3 (da) 2019-08-12
PL3191512T3 (pl) 2020-01-31

Similar Documents

Publication Publication Date Title
US11407822B2 (en) Treatment of fibrodysplasia ossificans progressiva
US20210061898A1 (en) Treatment of fibrodysplasia ossificans progressiva
HK1238260B (en) Treatment of fibrodysplasia ossificans progressiva
HK1238260A1 (en) Treatment of fibrodysplasia ossificans progressiva
US12344665B2 (en) Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
EA039118B1 (ru) Способ лечения прогрессирующей оссифицирующей фибродисплазии
BR112017004812B1 (pt) Uso de um anticorpo contra ativina a para preparação de um medicamento para tratamento de fibrodisplasia ossificante progressiva
HK1251898B (en) Treatment of fibrodysplasia ossificans progressiva

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

EEER Examination request

Effective date: 20200908

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218